Company Filing History:
Years Active: 2022
Title: Xuli Wang: Innovator in CD73 Inhibitors
Introduction
Xuli Wang is a prominent inventor based in Suzhou, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of CD73 inhibitors. His work focuses on innovative compounds that have the potential to treat various diseases, including cancer and immune-related disorders.
Latest Patents
Xuli Wang holds 1 patent for his invention titled "CD73 inhibitors and pharmaceutical uses thereof." This patent provides compounds that inhibit CD73, also known as ecto-5'-nucleotidase. The invention includes compositions and methods for treating or preventing CD73-associated diseases, disorders, and conditions. The CD73 inhibitor compounds feature a specific structure and include pharmaceutically acceptable esters or salts.
Career Highlights
Xuli Wang is currently employed at Risen (Suzhou) Pharma Tech Co., Ltd. His role at the company allows him to further his research and development efforts in the pharmaceutical industry. His innovative work has positioned him as a key figure in the advancement of treatments for serious health conditions.
Collaborations
Xuli Wang collaborates with talented professionals in his field, including Jiasheng Lu and Jiamin Gu. These collaborations enhance the research and development process, leading to more effective pharmaceutical solutions.
Conclusion
Xuli Wang's contributions to the field of CD73 inhibitors demonstrate his commitment to advancing medical science. His innovative work has the potential to impact the treatment of various diseases significantly.